Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
Research highlights Nu-3's rapid bactericidal activity against clinically relevant resistant pathogens and its potential as a topical treatment for infected diabetic foot ulcers SARASOTA, Fla., Oct. 21, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the...